Cell quality of apheresis-derived platelets treated with riboflavin-ultraviolet light after resuspension in platelet additive solution

Transfusion

Volumn 52, Issue 3, 2012, Pages 510-516

  Picker, Susanne M ^a   Tauszig, Marie E ^a   Gathof, Birgit S ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; MISCELLANEOUS DRUGS AND AGENTS; PLATELET ADDITIVE SOLUTION; RIBOFLAVIN; UNCLASSIFIED DRUG;

APHERESIS; ARTICLE; CELL SUSPENSION; CONTROLLED STUDY; HUMAN; HUMAN CELL; THROMBOCYTE; ULTRAVIOLET RADIATION;

ADENOSINE TRIPHOSPHATE; BLOOD PLATELETS; BLOOD PRESERVATION; CELL SURVIVAL; GLUCOSE; HUMANS; L-LACTATE DEHYDROGENASE; LACTIC ACID; MEMBRANE POTENTIAL, MITOCHONDRIAL; OSMOTIC PRESSURE; OXYGEN CONSUMPTION; PHOTOSENSITIZING AGENTS; PLATELETPHERESIS; RIBOFLAVIN; SOLUTIONS; ULTRAVIOLET RAYS;

EID: 84858175773     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2011.03323.x     Document Type: Article

References (30)

1. Busch MP, Kleinmann SH, Nemo GJ,. Current and emerging infectious risks of blood transfusion. JAMA 2003; 289: 959-62. (Pubitemid 37432916)
2. Allain JP, Bianco C, Blajchman MA, Brecher ME, Busch M, Leiby D, Lin L, Stramer S,. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. Transfus Med Rev 2005; 19: 110-26. (Pubitemid 40544291)
3. Ostrowski SR, Bochsen L, Salado-Jimena JA, Ullum H, Reynaerts I, Goodrich RP, Johansson PI,. In vitro cell quality of buffy coat platelets in additive solution treated with pathogen reduction technology. Transfusion 2010; 50: 2210-9.
4. Chernoff A, Snyder EL,. The cellular and molecular basis of the platelet storage lesion: a symposium summary. Transfusion 1992; 32: 386-90.
5. van Rhenen DJ, Vermeij J, Mayaudon V, Hind C, Lin L, Corash L,. Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy-coats. Vox Sang 2000; 79: 206-14. (Pubitemid 32046032)
6. Janetzko K, Klinger M, Mayaudon V, Lin L, Eichler H, Klüter H,. Storage characteristics of split double-dose platelet concentrates derived from apheresis and treated with amotosalen-HCl and UVA light for pathogen inactivation. Infus Ther Transfus Med 2002; 29: 193-8. (Pubitemid 34914045)
7. Li J, De Korte D, Woolum MD, Ruane PH, Keil SD, Lockerbie O, McLean R, Goodrich RP,. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products. Vox Sang 2004; 87: 82-90. (Pubitemid 39265454)
8. AuBuchon JP, Herschel L, Roger J, Taylor H, Whitley P, Li J, Edrich R, Goodrich RP,. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005; 45: 1335-41. (Pubitemid 41647801)
9. Goodrich RP, Li J, Pieters H, Crookes R, Roodt J, Heyns AP,. Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects. Vox Sang 2006; 90: 279-85.
10. Rinder HM, Smith BR,. In vitro evaluation of stored platelets: is there hope for predicting posttransfusion platelet survival and function? Transfusion 2003; 43: 2-6. (Pubitemid 36322890)
11. Rinder HM, Snyder EL, Tracey JB, Dincecco D, Wang C, Baril L, Rinder CS, Smith BR,. Reversability of severe metabolic stress in stored platelets after in vitro plasma rescue or in vivo transfusion: restoration of secretory function and maintenance of platelet survival. Transfusion 2003; 43: 1230-7. (Pubitemid 37082683)
12. Picker SM, Schneider V, Gathof BS,. Platelet function assessed by shear induced deposition of split triple-dose apheresis concentrates treated with pathogen reduction technologies. Transfusion 2009; 49: 1224-32.
13. Picker SM, Oustianskaia L, Schneider V, Gathof BS,. Cell viability during platelet storage in correlation to cellular metabolism after different pathogen reduction technologies. Transfusion 2009; 49: 2311-8.
14. 2) for pathogen reduction. Vox Sang 2009; 97: 26-2.
15. Picker SM, Oustianskaia L, Schneider V, Gathof BS,. Annexin V release and transmembrane mitochondrial potential during storage of apheresis-derived platelets treated for pathogen reduction. Transfus Med Hemother 2010; 37: 7-12.
16. Born GV, Cross MJ,. The aggregation of blood platelets. J Physiol 1963; 168: 178-95.
17. Fantl P,. Osmotic stability of blood platelets. J Physiol 1968; 198: 1-16.
18. Kilkson H, Holme S, Murphy S,. Platelet metabolism during storage of platelet concentrates at 22°C. Blood 1984; 64: 406-14. (Pubitemid 14051327)
19. Marschner S, Hansen E, Rouse L, Goodrich RP,. Platelet function under high-shear flow conditions after Mirasol® PRT treatment. Transfusion 2009; 49 Suppl: 87A.
20. Marschner S, Hansen E, Rouse L, Hovenga N, Goodrich RP,. In-vitro cell quality of platelets treated with Mirasol® PRT in the presence of PAS and gamma-irradiated at the beginning of storage. Transfusion 2009; 49 Suppl: 88A.
21. de Korte D, Vlaar R, Gouwerok E, Marschner S, Hansen E, Reynaerts I, Goodrich RP,. Mirasol® treatment of buffy coat platelets suspended in additive solution. Transfusion 2009; 49 Suppl: 85A.
22. Letowska M, Kubis J, Antoniewicz-Papis J, Dzieciatkowska A, Rosiek A, Wozniak J, Piotrowski D, Przybylska Z, Bykowska K, Lachert E,. Quality control of riboflavin treated platelet concentrates (Mirasol Prt system). Transfusion 2009; 49 Suppl: 101A.
23. Murphy S,. Platelet storage for transfusion. Semin Hematol 1985; 22: 165-77.
24. Gorlin JB, editor. Standards for blood banks and transfusion services. 21th ed. Bethesda (MD): American Association of Blood Banks; 2002.
25. Council of Europe. Guide to the preparation, use and quality assurance of blood components. 13th ed. Strassbourg: Council of Europe Publishing; 2007.
26. Perez-Pujol S, Tonda R, Lozano M, Fuste B, Lopez-Vilchez I, Galan AM, Li J, Goodrich R, Escolar G,. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion 2005; 45: 911-9. (Pubitemid 40798782)
27. Murphy S, Rebulla P, Bertolini F, Holme S, Moroff G, Snyder E, Stromberg R,. In vitro assessment of the quality of stored platelet concentrates. Trans Med Rev 1994; 8: 29-36. (Pubitemid 24024871)
28. Verhoeven AJ, Verhaar R, Gouwerok EG, de Korte D,. The mitochondrial membrane potential in human platelets: a sensitive parameter for platelet quality. Transfusion 2005; 45: 82-9.
29. Gawaz MP,. Blood platelets. New York: Georg Thieme Verlag Stuttgart; 2001.
30. Goodrich RP, Folléa G, Roberts T,. Clinical evaluation of Mirasol PRT treated apheresis platelets in thrombocytopenic patients. Transfusion 2008; 48: 20A.